CervoMed reports Q4/FY2024 results; positive Phase 2b extension data for neflamapimod in DLB

CervoMed Inc.

Cash $38.9M at Dec 31, 2024 (up from $7.8M); funded into mid-2026.
Net loss $16.3M for FY2024 vs $2.2M in 2023 (2023 included noncash gain).
Positive 16-week extension results: improvement on CDR-SB (p<0.001 vs old capsules; p=0.003 vs placebo).
Plan to initiate Phase 3 trial in mid-2026 after regulatory meetings.
Added senior VPs Claudia Ordonez (Medical Science) and Mark De Rosch (Regulatory).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.